Fig. 3: Colitis altered central endocannabinoid levels.
Following trinitrobenzene sulfonic acid (TNBS) administration, at Day 7, anandamide (AEA) levels were reduced in the (A) amygdala, (B) medial prefrontal cortex and (D) hippocampus, but not the (C) hypothalamus. Concomitantly, there was an increase in AEA’s metabolic enzyme’s (fatty acid amide hydrolase (FAAH)) activity (Vmax), in the (E) amygdala, (F) medial prefrontal cortex, with no differences in the (H) hippocampus or (G) hypothalamus. In contrast to AEA levels, Day 7 2-arachindonylyl glycerol (2-AG) levels were increased in the (J) medial prefrontal cortex, (L) hippocampus, and no significant changes occurred in the (I) amygdala or (K) hypothalamus with TNBS administration. There were no differences at Day 7 post-administration in the activity of 2-AG’s metabolic enzyme (monoacylglycerol lipase (MAGL); Vmax) in the (M) amygdala, (N) medial prefrontal cortex, (O) hypothalamus or (P) hippocampus from colitis. n = 9–12/group for levels and n = 4 = 6/group for enzyme activity. *p < 0.05, **p < 0.01, ****p < 0.0001, t test saline vs. TNBS. Saline = left, black bars with circles. TNBS = right, orange bars with squares.
